Actively Recruiting
Development and Application of Precision Treatment Strategies for Common Mental Disorders
Led by Peking University · Updated on 2024-12-12
600
Participants Needed
1
Research Sites
107 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Schizophrenia (SCH), major depressive disorder (MDD), and bipolar disorder (BPD) are prevalent, disabling psychiatric conditions that not only cause significant suffering for affected individuals and their families but also impose a substantial socioeconomic burden and challenge societal well-being. Addressing the mental health challenges faced by patients, their families, and the healthcare system is a critical global public health priority. However, a comprehensive and systematic precision treatment approach for mental disorders remains largely absent in current clinical practice. This study leveraged pharmacogenomic insights tailored specifically to the Chinese Han population to guide individualized medication selection. The approach incorporated quantitative assessment-based treatment protocols alongside therapeutic drug monitoring throughout the treatment process. The overarching goal was to establish a systematic precision treatment model that integrates "quantitative assessment-based treatment + pharmacogenomics + therapeutic drug monitoring." This model aims to optimize treatment outcomes, enhance safety, improve efficiency, and reduce costs, ultimately benefiting patients with psychiatric disorders.
CONDITIONS
Official Title
Development and Application of Precision Treatment Strategies for Common Mental Disorders
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 to 65 years, no gender restriction, Han ethnicity
- Diagnosis confirmed using the MINI tool meeting DSM-5 criteria for schizophrenia, depressive disorder, or bipolar disorder
- For schizophrenia: baseline PANSS score 260 or higher
- For depression: baseline HAMD-17 score 17 or higher
- For bipolar disorder: baseline YMRS score 13 or higher
- Education level of middle school or higher
- No language barriers and able to cooperate with assessment and treatment
- Informed consent obtained from patient or guardian
You will not qualify if you...
- History or current diagnosis of organic mental disorders, schizoaffective disorder, intellectual disability, dementia, other cognitive disorders, alcohol or drug dependence, and Axis II disorders including personality disorders
- Severe suicidal tendencies or risk of harming others
- Severe or unstable physical illnesses
- Narrow-angle glaucoma
- History of epilepsy or seizures
- Known pregnancy or breastfeeding, or planning to become pregnant
- Participation in another clinical trial or unwilling/unable to complete this trial
- Deemed unsuitable by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking University Sixth Hostipal
Beijing, Beijing Municipality, China, 100191
Actively Recruiting
Research Team
W
Weihua Yue
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here